Half of Annual Salary Paid as Bonus... SAMSUNG Biologics Achieves Record-High Results

SAMSUNG Biologics has reportedly set this year's Over-Performance Incentive (OPI, formerly PS) at 50% of annual salary.

According to industry sources on December 26, John Rim, CEO of SAMSUNG Biologics, sent an email to employees earlier this week announcing this year's OPI payment criteria.

The OPI is a representative performance-based bonus system at SAMSUNG, paid once a year when a business division exceeds the targets set at the beginning of the year. Within 20% of the excess profit, employees can receive up to 50% of their annual salary. The final payment is expected in January next year.

SAMSUNG Biologics has continued to set new record-high results each year, and as a result, the OPI cap will be applied again this year, following last year. In fact, the company achieved record results last year with consolidated sales of 4.5473 trillion won and operating profit of 1.3201 trillion won. Among domestic pharmaceutical and biotech companies, SAMSUNG Biologics was the first to surpass 4 trillion won in annual sales.

SAMSUNG Biologics Plant 4

Despite uncertainties in the external environment, such as U.S. tariff pressures, the company has continued to secure large-scale contracts with major global pharmaceutical companies, further solidifying its position as a global contract development and manufacturing organization (CDMO) partner.

Meanwhile, major SAMSUNG affiliates, including SAMSUNG Electronics, have not yet announced their OPI payment levels for this year, with related announcements expected sometime next week.